Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles

Pham, Le Minh; Poudel, Kishwor; Ou, Wenquan; Phung, Cao Dai; Nguyen, Hanh; Nguyen, Bao Loc; Karmacharya, Prajeena; Pandit, Mahesh; Chang, Jae‐Hoon; Jeong, Jee–Heon; Ku, Sae Kwang; Yong, Chul Soon; Choi, Han‐Gon; Kim, Jong Oh

doi:10.1016/j.ijpharm.2021.120816

Cited by 24 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, traditional taxanes cannot be effectively combined with immunotherapy because they require concurrent administration of steroids. However, studies have shown that nab‐paclitaxel can regulate the immune microenvironment and sensitize cancers to immunotherapy ( 128 – 130 ). This suggests that nab‐paclitaxel combined with immunotherapy for sarcomas may have a better curative effect.…”

Section: Discussionmentioning

confidence: 99%

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Tian

Yao

2022

Front. Oncol.

View full text Add to dashboard Cite

Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently approved for the treatment of advanced breast, non-small cell lung, and pancreatic cancers. However, the efficacy of nab-paclitaxel in sarcomas has not been reviewed. In this review, we first compare the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel and then summarize the efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results. The efficacy and clinical research progress on nab-paclitaxel in sarcomas are also summarized. This review will serve as a good reference for the application of nab-paclitaxel in clinical sarcoma treatment studies and the design of clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Tian

Yao

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The combined application of chemotherapy and immunotherapy has gradually become a current trend in cancer treatment. The monotherapy of the two has proven to be effective in increasing response and ameliorating prognosis among several cancers [68,69]. Thus, we investigated the association between NEIL3 expression and chemotherapeutic drug efficacy.…”

Section: Discussionmentioning

confidence: 99%

Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy

Liao

Huang

Lin

et al. 2022

Cancers

View full text Add to dashboard Cite

With the aim of enhancing the understanding of NEIL3 in prognosis prediction and therapy administration, we conducted a pan-cancer landscape analysis on NEIL3. The mutation characteristics, survival patterns, and immune features of NEIL3 across cancers were analyzed. Western blotting, qPCR, and immunohistochemistry were conducted to validate the bioinformatics results. The correlation between NEIL3 and chemotherapeutic drugs, as well as immunotherapies, was estimated. NEIL3 was identified as an oncogene with prognostic value in predicting clinical outcomes in multiple cancers. Combined with the neoantigen, tumor mutational burden (TMB), and microsatellite instability (MSI) results, a strong relationship between NEIL3 and the TME was observed. NEIL3 was demonstrated to be closely associated with multiple immune parameters, including infiltrating immunocytes and pro-inflammatory chemokines, which was verified by experiments. More importantly, patients with a higher expression of NEIL3 were revealed to be more sensitive to chemotherapeutic regimens and immune checkpoint inhibitors in selected cancers, implying that NEIL3 may be an indicator for therapeutic administration. Our study indicated NEIL3 has a strong association with the immune microenvironment and phenotypic changes in certain types of cancers, which facilitated the improved understanding of NEIL3 across cancers and highlighted the potential for clinical application of NEIL3 in precision medical stratification.

show abstract

“…This formulation was combined with separately administered CTLA-4 antibody for treatment evaluations. In an EMT-6 tumor xenograft model, the NPs combined with free anti-CTLA-4 were able to decrease tumor mass by ~80%, in contrast to ~60% decrease without CTLA-4 antibody, and ~40% with nab-paclitaxel only ( 38 ). In another study, an oleic acid conjugated polyethyleneimine polymer complex was formed and loaded with paclitaxel, chloroquine (an autophagy inhibitor), ovalbumin (antigen), CpG (immunoadjuvant), and anti-PD-L1 antibody, through a thin-film hydration and a self-assembly process.…”

Section: Nanoparticles Co-loaded With Pd-l1 Inhibitor and Other Forms...mentioning

confidence: 99%

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Linde,

Chien,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer with triple-negative subtype (TNBC) presents significant challenges with limited treatment options and a poorer prognosis than others. While PD-1/PD-L1 checkpoint inhibitors have shown promise, their efficacy in TNBC remains constrained. In recent years, nanoparticle (NP) technologies offer a novel approach to enhance cancer therapy by optimizing the tumor microenvironment and augmenting chemo- and immunotherapy effects in various preclinical and clinical settings. This review discusses recent investigations in NP strategies for improving PD-1/PD-L1 blockade-based combination therapy for TNBC. Those include single or multi-therapeutic NPs designed to enhance immunogenicity of the tumor, induce immunogenic cell death, and target immunosuppressive elements within the tumor microenvironment. The investigations also include NPs co-loaded with PD-L1 inhibitors and other therapeutic agents, leveraging targeted delivery and synergistic effects to maximize efficacy while minimizing systemic toxicity. Overall, NP approaches represent a promising avenue for enhancing PD-1/PD-L1 checkpoint blockade-based combination therapy in TNBC and encourage further developmental studies.

show abstract

Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles

Cited by 24 publications

References 72 publications

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Contact Info

Product

Resources

About